Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer's disease.

ABSTRACT: As individuals age, microglia, the resident immune cells of the central nervous system (CNS), become less effective at preserving brain circuits. Increases in microglial inflammatory activity are thought to contribute to age-related declines in cognitive functions and to transitions toward mild cognitive impairment (MCI) and Alzheimer's disease (AD). As microglia possess receptors for communicating with the CNS environment, pharmacological therapies targeting these pathways hold potential for promoting homeostatic microglial functions within the aging CNS. Preclinical and early phase clinical trials investigating the therapeutic effects of pharmacological agents acting on microglia, including reactive oxygen species, TREM2, fractalkine signaling, the complement cascade, and the NLRP3 infla

SUBMITTER: McKee CG 

PROVIDER: S-EPMC10034122 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature